Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid in Compensated Cirrhosis Due to NASH (Phase 3)
2017-000474-11Phase 3Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis due to nonalcoholic steatohepatitis comparing Obeticholic acid with Placebo (2 arms). Primary endpoint: Histologic improvement in fibrosis. Started Apr 2018; status: completed.
02
Drugs
obeticholic acid
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)cirrhosis due to nonalcoholic steatohepatitis
Beyond the preview
Go deeper on 2017-000474-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000474-11.